Hormonal contraception and venous thromboembolism

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 7, 2012, Pages 769-778

  Lidegaard, Øjvind ^a   Milsom, Ian ^b   Geirsson, Reynir Tomas ^c   Skjeldestad, Finn Egil ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Deep venous thrombosis; Drospirenone; Hormonal contraception; Levonorgestrel; Oral contraceptives; Venous thromboembolism

Indexed keywords

DESOGESTREL; DROSPIRENONE; GESTAGEN; GESTODENE; LEVONORGESTREL; LOW DOSE ORAL CONTRACEPTIVE; NORETHISTERONE; NORGESTIMATE;

ACTIVATED PROTEIN C RESISTANCE; GENETIC PREDISPOSITION; HORMONAL CONTRACEPTION; HUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; VAGINA RING; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL; FEMALE; HUMANS; INCIDENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84862887724     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2012.01444.x     Document Type: Review

References (34)

1. ESHRE CapriWorkshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11:513-25.
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95:385-9.
3. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 2007;335:651-9.
4. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593-6.
5. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-82.
6. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of ideopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589-93.
7. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of YoungWomen. BMJ. 1996;312:83-8.
8. Lewis MA, MacRae KD, Kühl-Habich D, Bruppacher R, Heinemann LAJ, SpitzerWO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod. 1999;14:1493-9.
9. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83-8.
10. Todd J-C, Lawrenson R, Farmer RDT,Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod. 1999;14:1500-5.
11. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Int Med. 1999;159:65-70.
12. Parkin L, Skegg DCG,Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet. 2000;355:2133-4.
13. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A five-year national case-control study. Contraception. 2002;65:187-96.
14. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women years of observation. Contraception. 2007;75:344-54.
15. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestagen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
16. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
17. Dinger J, Assmann A, Möhner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care. 2010;36:123-9.
18. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;340:d2139.
19. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;340:d2151.
20. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen doses: Danish cohort study 2001-9. BMJ. 2011;343:d6423.
21. Food and Drug Adminidsration, Office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. FDA, 2011. Available online at: http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM277384.pdf (accessed May 12, 2012).
22. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183:E1319-25.
23. Lidegaard Ø, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344: e2990.
24. InmanWHW, Vessey MP,Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J. 1970;2:203-9.
25. Böttiger LE, Boman G, Eklund G,Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering estrogen content. Lancet. 1980;8178:1097-101.
26. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular actions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg estrogen preparations. Br Med J. 1980;280:1157-61.
27. Effect of different progestogens in low estrogen oral contraceptives on venous thromboembolic disease.World Health Organization Collaborative Study on Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582-8.
28. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand. 2002;81:482-90.
29. Raps M, Helmerhorst F, Fleischer K, Thomassen S, Rosendaal F, Rosing J, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012. doi:10.1111/j.1538-7836.2012. 04720.x.
30. Van Vliet HAAM,Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproteroneacetate. J Thromb Haemost. 2004;2:2060-2.
31. Effect on stroke of different progestagens in low estrogen dose oral contraceptives.WHO Collaborative Study of Cardiovascular Disease and Steriod Hormone Contraception. Lancet. 1999;354:301-2.
32. Lidegaard Ø, Kreiner S. Oral contraceptives and cerebral thrombosis. A five-year national case-control study. Contraception. 2002;65:197-205.
33. Heinemann LAJ, LewisMA, SpitzerWO, Thorogood M, Guggenmoss-Holzmann I, Bruppacher R. Thromboembolic stroke in young women. Contraception. 1998;57:29-37.
34. Lidegaard Ø, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66.